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Knowledge on toxin immunogenicity at the molecular level can provide valuable infor-
mation for the improvement of antivenoms, as well as for understanding toxin structure–
function relationships. The aims of this study are two-fold: ﬁrst, to identify the linear
B-cell epitopes of myotoxin II from Bothrops asper snake venom, a Lys49 phospholipase A2
homologue; and second, to use antibodies speciﬁcally directed against an epitope having
functional relevance in its toxicity, to probe the dimeric assembly mode of this protein in
solution. Linear B-cell epitopes were identiﬁed using a library of overlapping synthetic
peptides spanning its complete sequence. Epitopes recognized by a rabbit antiserum to
puriﬁed myotoxin II, and by three batches of a polyvalent (Crotalidae) therapeutic anti-
venom (prepared in horses immunized with a mixture of B. asper, Crotalus simus, and
Lachesis stenophrys venoms) were mapped using an enzyme-immunoassay based on the
capture of biotinylated peptides by immobilized streptavidin. Some of the epitopes
identiﬁed were shared between the two species, whereas others were unique. Differ-
ences in epitope recognition were observed not only between the two species, but also
within the three batches of equine antivenom. Epitope V, located at the C-terminal region
of this protein, is known to be relevant for toxicity and neutralization. Afﬁnity-puriﬁed
rabbit antibodies speciﬁc for this site were able to immunoprecipitate myotoxin II, sug-
gesting that the two copies of epitope V are simultaneously available to antibody binding,
which would be compatible with the mode of dimerization known as “conventional”
dimer.
 2012 Elsevier Ltd. All rights reserved.1. Introduction
Serotherapy, discovered over a century ago, stands
amongst the signiﬁcant medical contributions of immu-
nology, saving thousands of patients who suffer from
envenomings every year (Bon, 1996; Kasturiratne et al.,
2008; Harrison et al., 2009). Therapeutic antivenoms are
conventionally prepared by injecting one or several venoms
as immunogens in animals, aiming to elicit high levels of
antibodies that bind to and neutralize their most relevant
toxins, if not all. Therefore, elucidating the immunological. All rights reserved.properties of toxic venom components is a medically
relevant task (Ménez, 1985).
Immunological characteristics of venoms can be
analyzed at various levels, i.e. focusing on either whole
venom secretions, individual toxin molecules, or their
submolecular antigenic sites. Considering whole toxin
molecules as “study units”, features such as their immu-
nogenity, antigenic cross-reactivity, and neutralization by
antibodies contained in speciﬁc or paraspeciﬁc antisera
can be evaluated. Further, immunological properties of
toxins can be analyzed at a molecular level, by studying
details of their ﬁne antigenic structure (Ménez, 1985).
Such studies aim to delineate toxin epitopes for B and T
lymphocytes of immunized animals, to identify which
B. Lomonte / Toxicon 60 (2012) 782–790 783epitopes are recognized by neutralizing antibodies, and
to elucidate the molecular mechanisms that underlie
such neutralization. All these types of approaches, i.e.
focusing on crude venoms, on toxin molecules, or on their
submolecular antigenic structures, provide useful infor-
mation for the rational design, development, and clinical
use of antivenoms (Ménez, 1985; Dias da Silva et al., 1989;
Wagstaff et al., 2006; Stock et al., 2007; Espino-Solis et al.,
2009; Gutiérrez et al., 2009; Calvete et al., 2009; Calvete,
2010).
Although the antigenic structure of some snake venom
toxins, for example the a-neurotoxins of the three-ﬁnger
toxin family, has been extensively studied (Ménez, 1985),
the immunological properties of many toxin types remain
largely unexplored. In the case of phospholipase A2 (PLA2)
toxins, which are abundant and clinically relevant compo-
nents of many snake venoms, immunological studies
have mainly focused on those having potent neurotoxic
activities, and have shown that elapid and viperid PLA2s
form two distinct antigenic classes (Kaiser et al., 1986;
Henderson and Bieber, 1986; Middlebrook and Kaiser, 1989;
Choumet et al., 1989, 1991, 1992; Mollier et al., 1989, 1990;
Curin-Serbek et al., 1991; Stiles and Middlebrook, 1991;
Middlebrook, 1991; Basavarajappa et al., 1993; Alape-Girón
et al., 1994; Cardoso et al., 2000; Demangel et al., 2000),
in agreement with their evolutionary divergence into
structural groups I and II, respectively (Schaloske and
Dennis, 2006).
Within the venom PLA2s from viperids (group II),
a subdivision deﬁned by the amino acid occupying position
49 exists: catalytically-active PLA2s invariably present
Asp49, whereas a subgroup of catalytically-inactive PLA2
homologues most frequently present the substitution of
this residue by Lys49 (Lomonte et al., 2003; Lomonte and
Rangel, in press). All proteins of the Lys49 subgroup
share the property of inducing skeletal muscle necrosis at
the site of injection, therefore being classiﬁed as locally-
acting myotoxins (Lomonte and Gutiérrez, 2011). Due to
their abundance in the venoms of many viperids (Lomonte
et al., 2009), and considering the clinical signiﬁcance of
myonecrosis in snakebite envenomings by such species
(Cardoso et al., 1993; Otero et al., 2002), the Lys49 myo-
toxins represent important targets for neutralization by
therapeutic antivenoms.
Some immunological aspects of the Lys49 myotoxins
and their neutralization have been previously investigated
using polyclonal and monoclonal antibodies (Lomonte
et al., 1990b, 1992; Moura-da-Silva et al., 1991; Calderón
and Lomonte, 1998; Angulo et al., 2001), but their
immunorecognition at the molecular level has not been
explored comprehensively. In the present study, a library
of overlapping synthetic peptides spanning the complete
sequence of myotoxin II from Bothrops asper was utilized
to identify linear B-cell epitopes for the ﬁrst time in
a Lys49 PLA2 homologue. Epitopes recognized by rabbit
antibodies elicited by immunization with puriﬁed myo-
toxin II, or by horse antibodies present in therapeutic
antivenoms, elicited by immunization with a mixture of
crude venoms, were compared. As an additional aim of
this immunological study, antibodies directed against an
epitope located at the C-terminal region of myotoxin II,known to be relevant for toxicity, were used as a probe
to explore the possible dimeric assembly mode of this
protein in solution.
2. Materials and methods
2.1. Toxin isolation
B. asper venomwas a pool obtained from at least twenty
adult specimens from the Caribbean region of Costa
Rica, maintained at the serpentarium of Instituto Clodo-
miro Picado (University of Costa Rica). The venom was
lyophilized and kept at 20 C. Myotoxin II was isolated
from this venom by ion-exchange chromatography on
CM-Sephadex C25 as described (Lomonte and Gutiérrez,
1989), followed by RP-HPLC on a C8 semi-preparative
column (10  250 mm; Vydac) eluted at 2.0 mL/min with
a 0–70% acetonitrile gradient containing 0.1% triﬂuoro-
acetic acid, during 30 min, on an Agilent 1200 instrument
monitored at 215 nm. Toxin homogeneity was evaluated by
MALDI-TOF mass spectrometry on an Applied Biosystems
4800-Plus instrument operated in positive linear mode,
using sinapic acid as matrix, as previously described
(Fernández et al., 2011).
2.2. Synthetic peptides
A library of 56 overlapping synthetic peptides
(PepSets), spanning the complete sequence of myotoxin II
(P24506), was obtained from Mimotopes, Inc. (Minneap-
olis, USA). The offset of peptides was two amino acids.
Peptides were biotinylated at the N-terminus, consisting of
a tetrapeptide spacer arm (SGSG) followed by a dodecamer
corresponding to each myotoxin II sequence segment,
ending with an amidated C-terminus. This library was
utilized in an enzyme-immunoassay for the linear epitope
scanning of myotoxin II. The synthetic peptide KKYR-
YYLKPLCKK, corresponding to the sequence 115-129 of
myotoxin II (p115-129), coupled to diphteria toxoid, was
utilized to raise rabbit antibodies to this region, as previ-
ously described (Calderón and Lomonte, 1998). Sequence
numbering follows the scheme described by Renetseder
et al. (1985).
2.3. Serum antibodies
Antiserum to myotoxin II was prepared by immuniza-
tion of a white New Zealand female rabbit with the puri-
ﬁed toxin, using complete Freund’s adjuvant for priming
(1 mg of toxin) and sodium alginate adjuvant for booster
injections (0.25 mg) at three-week intervals, by i.m. route,
during four months. Rabbit antiserum to synthetic
peptide p115-129-diphteria toxoid was prepared similarly
(Calderón and Lomonte, 1998). Antibodies to p115-129
were puriﬁed by afﬁnity-chromatography on a column of
myotoxin II immobilized onto CNBr-activated Sepharose
4B beads (GE Healthcare). Three batches of equine anti-
venom (Crotalidae polyvalent; 424LQ, 447LQ, and 466LQ),
were provided by the Industrial Division of Instituto Clo-
domiro Picado. This antivenom consists of caprylic acid-
puriﬁed, undigested immunoglobulins from the plasma
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B. asper, Crotalus simus, and Lachesis stenophrys (Rojas
et al., 1994).
2.4. Enzyme-immunoassay
Ninety-six well microplates (Nunc-Maxisorp) were
coated with streptavidin (0.5 mg/well) dissolved in 100 mL
of 0.1 M Tris, 0.15 M NaCl buffer, pH 9.0, overnight at
room temperature. After ﬁve washings with 0.12 M NaCl,
0.04 M sodium phosphate buffer, pH 7.2 (PBS), wells were
blocked with bovine serum albumin (BSA; 1% in PBS) for
1 h, and then washed four times with PBS containing
0.05% Tween-20 (PBS-T). Biotinylated synthetic peptides
(Section 2.2) were reconstituted in 40% acetonitrile/water
at 10–15 mg/mL and stored as stock solutions at 20 C.
Peptide stocks were diluted 1:500 with PBS-T, and incu-
bated into the streptavidin-coated wells for 1 h at room
temperature. After four washings with PBS-T, either
rabbit or horse antisera diluted 1:2000 in PBS-0.1% BSA
were added and incubated for 2 h. After washing simi-
larly, bound antibodies were detected by adding the
corresponding anti-immunoglobulin/alkaline phospha-
tase conjugates (1:3000; Sigma-Aldrich) diluted in PBS-
0.1% BSA for 1 h, followed by washing and ﬁnal colour
development with p-nitrophenylphosphate. Absorbances
were recorded at 405 nm on a Multiskan FC-Thermo
reader. Each peptide was assayed in duplicate wells.
Non-immune sera of the corresponding animal species
were utilized as negative controls to set the background
values. Identiﬁcation of a linear epitope was considered
positive when an absorbance signal higher than two-fold
the background value was recorded on at least two
adjacent peptides.
2.5. Gel immunodiffusion
The ability of afﬁnity-puriﬁed rabbit anti-p115-129
antibodies to immunoprecipitate myotoxin II was tested
by gel immunodiffusion. Wells in 1% agarose-PBS were
ﬁlled with toxin (50 mg) or antibodies (125 mg) in a volume
of 30 mL, and allowed to diffuse overnight. The gel was
exhaustively washed with PBS before staining the immu-
noprecipitate with amidoblack 10B, and ﬁnally destaining
the background with 5% acetic acid.
2.6. Molecular visualization
The structure coordinates of myotoxin II (PDB code
1CLP; Arni et al., 1995) were employed to visualize
the location of linear epitopes recognized by the anti-
myotoxin II rabbit serum, or by the three samples of
polyvalent equine antivenom. The crystal structure of
a monoclonal IgG (1IGT) served to compare the molecular
dimensions of an antibody relative to the epitope corre-
sponding to the C-terminal region 115-129 of myotoxin II.
Molecular images were prepared with RasWin v.2.7.5
(Biomolecular Structures Group, Glaxo Wellcome
Research & Development) and DSViewer v.6.0 (Accelrys)
software.3. Results and discussion
In spite of the relevance of myotoxic PLA2s from viperid
venoms in the development of muscle tissue damage and
potential sequelae in snakebites (Gutiérrez and Lomonte,
1995; Cardoso et al., 1993; Otero et al., 2002), insufﬁ-
cient work has been addressed at characterizing the
antibody response to these antigens at the molecular
level. Previous studies have shown that Lys49 myotoxins
from different viperid species present signiﬁcant immu-
nochemical cross-reactivity (Lomonte et al., 1987, 1990a;
Moura-da-Silva et al., 1991; Díaz et al., 1992; Angulo et al.,
1997; Calderón and Lomonte, 1998), in agreement with
the high amino acid sequence similarity among members
of this toxin family. On this basis, present results obtained
using B. asper myotoxin II might be useful to the immu-
nological characterization of similar Lys49 myotoxins as
well.
B-cell epitopes can be divided into two
categories, conformational/discontinuous or linear/
continuous (Worthington and Morgan, 1994). The former
are more difﬁcult to identify, being assembled by amino
acids located at non-contiguous sites which are brought
together by protein folding. In contrast, linear epitopes are
more easily reproduced by currently available techniques
for custom synthesis of peptides. The immunoassay
design here utilized has the advantage of avoiding the
direct binding of peptides to the solid-phase, thus
minimizing their possible conformational alterations.
Capturing of peptides in solution was possible by using an
N-terminal biotin tag and solid-phase adsorbed strepta-
vidin. In addition, a tetrapeptide spacer in each peptide
(SGSG) provided an increased distance between the
immobilized streptavidin and the dodecameric antigenic
probe, reducing steric hindrance effects in the immuno-
assay. With this design, several linear epitopes were
identiﬁed in myotoxin II, when probed against rabbit
(Fig. 1) and horse (Fig. 2) hyperimmune sera. Some of the
epitopes were shared between the two species, whereas
others were unique. A gradient of immunodominance
among the different epitopes was also observed, as
implied from the variable intensities of the immunoassay
signals obtained. Some of the linear epitopes identiﬁed
were weak (VI, VII, VIII), especially in the case of the
equine antivenoms (Fig. 2). Strongest reactivity in the
rabbit serum was observed against epitopes III and IV
(Fig. 1), whereas the three equine antivenoms had in
common a marked preference for epitope II (Fig. 2), which
was also signiﬁcantly recognized by the rabbit antibodies.
Differences in epitope recognition were observed not only
between the two species, but alsowithin the three batches
of horse-derived antivenom. Such variability is expected
on the basis of the different genetic constitution of
individuals within a species, especially at their MHC loci
(Benacerraf, 1981). The location of the identiﬁed epitopes
for both rabbit and horse antibodies in the three-
dimensional structure of a myotoxin II monomer is
comparatively represented in Fig. 3.
Depending on the functional consequences of antibody
binding to a toxin, epitopes can be classiﬁed as neutralizing
or non-neutralizing. In the case of myotoxin II, previous
Fig. 1. Linear epitopes recognized by rabbit serum antibodies to Bothrops asper myotoxin II. A library of 56 biotinylated synthetic peptides of myotoxin II
(dodecamers, with an overlapping offset of two), bound to streptavidin-coated 96-well plates, was incubated with immune rabbit serum (anti-Mt-II) or non-
immune rabbit serum (normal). Bound antibodies were detected colorimetrically by enzyme-immunoassay, as described in Materials and Methods. Absor-
bance signals higher than two-fold the value of normal serum background controls, and occurring in at least two contiguous peptides, were considered as linear
epitopes (labeled in roman numerals). The amino acid sequences corresponding to the recognized peptides are indicated, with shared sequences in boldface and
underlined. Amino acid sequence numbering follows Renetseder et al. (1985).
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the C-terminal region 115-129 inhibit its toxic actions
(Calderón and Lomonte, 1998). Thus, the epitope here
identiﬁed as “V”, spanning residues 117-128, is of func-
tional interest. Although the rabbit serum to myotoxin II
clearly recognized it, only one out of the three batches of
equine antivenom contained antibodies to this epitope.
This ﬁnding is in agreement with the earlier observation
that, although antibodies to this site can be raised by
immunization with a synthetic peptide, this particular
region is not strongly immunodominant in the antibody
response against the complete toxin, or against crude
venoms containing the toxin. A previous screening of
different batches of polyvalent-Crotalidae equine anti-
venom showed that only seldom they contained antibodies
against region 115-129 of myotoxin II (Calderón and
Lomonte, 1998), essentially corresponding to epitope V.
Moreover, immunization of mice with intact myotoxin II
did not induce signiﬁcant levels of antibodies to peptide
115-129, whereas a strong antibody response to this
epitope was obtained by immunization of mice with the
corresponding synthetic peptide (Calderón and Lomonte,
1999).
Excluding epitope V, it remains to be determined if
other epitopes identiﬁed in the present study lead to toxin
neutralization or not. This will require generating speciﬁc
antibodies against each of these epitopes and testing their
neutralizing ability. Although the myotoxic PLA2s are rela-
tively small proteins in comparison to antibodies, previous
investigations using a set of seven mouse monoclonal
antibodies demonstrated the existence of both neutralizing
and non-neutralizing epitopes (Lomonte and Kahan, 1988;Lomonte et al., 1992). However, the epitopes recognized by
these monoclonal antibodies were of the conformational
type, and could not be identiﬁed by using linear synthetic
peptide strategies.
The molecular characterization of epitopes on toxins
encloses potential beneﬁts, both from an applied and
a basic perspective. Neutralizing epitopes have been used
as synthetic immunogens to raise antisera against
a variety of toxin types, including snake venom metal-
loproteinases (Ferreira et al., 2006; Cardoso et al., 2009;
de Avila et al., 2011) and PLA2s (Demangel et al., 2000),
scorpion neurotoxins (Calderon-Aranda et al., 1999;
Gazarian et al., 2005), or spider dermonecrotic toxins
(Dias-Lopes et al., 2010), among other examples. In the
case of myotoxin II, immunization of mice with its
C-terminal synthetic peptide 115-129 induced antibodies
that prevented by 40% the muscle damage induced by
an experimental toxin challenge, in comparison to
non-immunized animals (Calderón and Lomonte, 1999).
Nevertheless, protection from myonecrosis in such model
was still lower than that obtained by immunization with
the intact toxin. The present observation that linear
epitopes III and IV (in rabbit serum) and II (in equine
antivenoms) display stronger recognition by antibodies
than other toxin regions, prompts for an exploration of
their potential as immunogens in future studies, aiming
to enhance the levels of anti-myotoxin antibodies during
equine antivenom production. In this regard, it is relevant
to note that antivenomic analyses based on HPLC-
immunodepletion and immunoblotting techniques have
recently disclosed that the antibody response to snake
venom PLA2s is sometimes insufﬁcient, suggesting that
Fig. 2. Linear epitopes of Bothrops asper myotoxin II recognized by equine antibodies from three batches of therapeutic polyvalent (Crotalidae) antivenom. A
library of 56 biotinylated synthetic peptides of myotoxin II (dodecamers, with an overlapping offset of two), bound to streptavidin-coated 96-well plates, was
incubated with three equine polyvalent antivenoms (A, PA-424; B, PA-447; C, PA-466) or non-immune equine immunoglobulins (normal). Bound antibodies were
detected colorimetrically by enzyme-immunoassay, as described in Materials and Methods. Absorbance signals higher than two-fold the value of the corre-
sponding normal background controls, and occurring in at least two contiguous peptides, were considered as linear epitopes (labeled in roman numerals, and
continuing the numbering in Fig. 1). The amino acid sequences corresponding to the recognized peptides are indicated, with the shared sequences in boldface and
underlined. Amino acid sequence numbering follows Renetseder et al. (1985).
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(15 kDa) may be limited (Lomonte et al., 2008; Antúnez
et al., 2010; Fernández et al., 2011; Calvete et al., 2011).
Similarly, an evaluation of anti-myotoxin antibodies
present in various therapeutic antivenoms by means ofenzyme-immunoassay revealed in some cases unex-
pectedly low titers (Lomonte et al., 1991). Manipulation of
the immune response during antivenom production, for
example by using synthetic peptides that represent
neutralizing toxin epitopes, or recombinant DNA strings
Fig. 3. Mapping of linear epitopes recognized by rabbit (A,C) and horse (B, D) antibodies on Bothrops asper myotoxin II. The three-dimensional structure of
a myotoxin II monomer (PDB code 1CLP; Arni et al., 1995) is represented in ribbons (top) or in space-ﬁlling view (bottom). The location of linear epitopes
identiﬁed from data in Fig. 1 (rabbit antibodies) and Fig. 2 (horse antibodies) is shown with different colours on a grey backbone, and indicating the sequence
numbering of the segments. Epitopes with shared recognition by antibodies from both species are coloured identically. In panels C and D, epitopes providing the
strongest signals in the analyses from Fig. 1 (III and IV) and 2 (II) are indicated by asterisks. Images were prepared with RasWin v.2.7.5. For interpretation of
colours the reader is referred to the web version of the article.
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useful to enhance the efﬁcacy of these products against
particularly relevant toxins which may be naturally weak
as immunogens.
From a basic point of view, epitope mapping offers
some possibilities to study the structure–function rela-
tionships of toxins. Lys49 myotoxins exist mainly as
homodimers in solution (Lomonte and Rangel, in press),
but two contrasting modes of dimerization have been
described by crystallographic analyses, referred to as
“conventional” (Arni et al., 1995; da Silva Giotto et al.,
1998) and “alternative” (dos Santos et al., 2009) dimers
(Fig. 4). It is still controversial if both types of quaternary
structural arrangements can occur in these toxins, or if
only one of these models is the correctly deduced form.
Myotoxin II was originally described as a “conventional”
dimeric assembly (Arni et al., 1995), but several other
related Lys49 myotoxins have been more recently
reported as “alternative” dimers (dos Santos et al., 2009,
2010). For this reason, as a second aim of the present
study, an exploration of the spatial availability of the
region corresponding to epitope V of myotoxin II wasattempted, using the afﬁnity-puriﬁed rabbit antibodies to
peptide 115-129 in a gel immunodiffusion assay. As
shown in Fig. 4, these site-speciﬁc antibodies were
capable of precipitating myotoxin II, therefore implying
the simultaneous availability of the two copies of epitope
V (in the toxin dimer), to the binding by two independent
antibody molecules needed to grow multimolecular
complexes large enough to precipitate. Due to the larger
size of antibodies relative to the toxin (proportionally
represented in Fig. 4), it would seem difﬁcult that
multivalent binding of the toxin may have occurred if its
structure corresponded to the “alternative” dimeric
assembly, due to the steric hindrance imposed by the
antibody paratope in the vicinity of its recognized
epitope (Fig. 4). In contrast, the distance between the two
copies of epitope V in the “conventional” dimer model
would seem compatible with the formation of multimeric
antigen–antibody complexes. Although this experiment
only provides an indirect structural evidence, and as such
should be interpreted with caution, it would be in
agreement with the originally proposed “conventional”
mode of dimerization for myotoxin II.
Fig. 4. Implications of the spatial availability of epitope V for the dimeric assembly of Bothrops asper myotoxin II, as inferred from immunoprecipitation. Rabbit
antibodies to a synthetic peptide representing the sequence 115-129 of myotoxin II were raised by immunization with diphteria toxoid-conjugated peptide. The
obtained antibodies were puriﬁed by afﬁnity-chromatography on a column of Sepharose 4B-myotoxin II, and tested by agarose gel double immunodiffusion
against this toxin. As shown in C, antibodies to p115-129 formed an immunoprecipitation line (arrow), implying the formation of multimolecular complexes
between the divalent IgG molecules and the dimeric toxin. Two possible modes of dimerization of myotoxin II are represented in panels B (“conventional” dimer)
and D (“alternative” dimer), respectively, showing the location of the sequence 115-129 in red, corresponding to epitope V (see Figs. 1–3). Panel A compares the
scaled molecular dimensions of an IgG (PDB code 1IGT) relative to those of myotoxin II in a conventional (left) or an alternative (right) dimeric assembly. Notice
the spatial separation of the two repeats of epitope V (red) in the conventional dimeric assembly, which could allow the simultaneous binding of two IgG
molecules needed for immunoprecipitation, in contrast to the spatial restraints imposed by the alternative dimeric assembly, where the proximity of the two
repeats of epitope V (red) would be expected to cause steric hindrance after the binding of a single antibody paratope, thereby precluding the growth of
complexes. Molecular images were prepared with DSViewer 6.0, shown in ribbons representation with semi-transparent molecular surfaces. For interpretation of
colours the reader is referred to the web version of the article.
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